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The ACCOMPLISH trial (Avoiding Cardiovascular events
through Combination therapy in Patients Living with Systolic
Hypertension) was a 3-year multicenter, event-driven trial
involving patients with high cardiovascular risk who were
randomized in a double-blinded manner to benazepril plus
either hydrochlorothiazide or amlodipine and titrated in
parallel to reach recommended blood pressure goals. Of the
8125 participants in the United States, 1414 were of self-
described Black ethnicity. The composite kidney disease end
point, defined as a doubling in serum creatinine, end-stage
renal disease, or death was not different between Black and
non-Black patients, although the Blacks were significantly
more likely to develop a greater than 50% increase in serum
creatinine to a level above 2.6mg/dl. We found important
early differences in the estimated glomerular filtration rate
(eGFR) due to acute hemodynamic effects, indicating that
benazepril plus amlodipine was more effective in stabilizing
eGFR compared to benazepril plus hydrochlorothiazide in
non-Blacks. There was no difference in the mean eGFR loss in
Blacks between therapies. Thus, benazepril coupled to
amlodipine was a more effective antihypertensive treatment
than when coupled to hydrochlorothiazide in non-Black
patients to reduced kidney disease progression. Blacks have a
modestly higher increased risk for more advanced increases
in serum creatinine than non-Blacks.
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Hypertension in Black patients compared with non-Black
patients is characterized by early onset, higher blood pressure
elevations, and a greater propensity to develop progressive
hypertensive renal injury.1–5 Numerous factors contribute to
the increased risk for renal disease in Blacks. These include a
mixture of biologic, sociologic, environmental, and socio-
cultural variables.6–12
Black patients with hypertension also have a somewhat
different response to blood pressure-lowering medications
compared with their non-Black counterparts.13,14 Blacks
appear to be less sensitive to renin–angiotensin system (RAS)-
blocking drugs and b-blockers than to thiazide diuretics
and calcium channel blockers.13,15 Yet, Black hypertensive
patients with kidney disease obtain benefit from RAS-block-
ing drugs such as angiotensin converting enzyme (ACE)
inhibitors in delaying both progression of kidney disease and
cardiovascular events.16 Given that many Black hypertensive
patients require more than one drug to achieve target blood
pressure, an important question is whether it is better to
combine a RAS-blocking drug, such as an ACE inhibitor,
with a thiazide diuretic or a calcium channel blocker to
control blood pressure and reduce kidney and cardiovascular
events more effectively. The results of the main ACCOM-
PLISH (Avoiding Cardiovascular events through Combina-
tion therapy in Patients Living with Systolic Hypertension)
study demonstrated greater overall cardiovascular benefit
from the combination of a calcium blocker (amlodipine (A))
vs. a thiazide diuretic (hydrochlorothiazide (H)) with an ACE
inhibitor (benazepril (B)).17 This paper represents a post-hoc
analysis of this trial focused on ethnic differences in kidney
disease outcomes in US participants. This evaluation was
performed as the Black cohort of this trial was large enough
to examine some potential differences in risk for kidney
disease progression.
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RESULTS
Study population
In total, 11,506 patients were randomized to the main study,
including 1416 patients of self-described Black race/ethnicity
and 10,089 patients who described their race as other than
Black (1 patient had no recorded demographic data). Mean
exposure was 2.5 years and mean follow-up was 3.0 years. Only
1% of patients were considered permanently lost to follow-up.
Because almost all Black participants were in the United States,
and the US and non-US non-Black participants differed with
regard to many characteristics (data not shown), the present
analyses were performed in US participants.
In the US sample, 1414 described themselves as Black and
6738 described themselves as non-Black. US Blacks were
younger (mean¼ 66.8 vs. 68.7 years), more often female
(59.8 vs. 39.6%), and less likely to have preexisting cardio-
vascular disease (31.3 vs. 51.5%) but more likely to have
diabetes (73.6 vs. 61.9%) and kidney disease (11.7 vs. 6.1%;
Table 1). In the Black group, 696 received BþA, whereas 718
received BþH.
In Table 1, one can examine the demographic and baseline
characteristics by ethnicity and treatment. One can see that,
although there are significant differences by ethnicity, when
we evaluate the treatment (BþA or BþH) by ethnicity
Table 1 | Demographic and baseline characteristics of the US patients – by ethnicity and treatment
Black Black Non-Black Non-Black
Black vs.
non-Black
B+A vs.
B+H
Treatment by
ethnicity
interaction
Characteristic B+A B+H B+A B+H P-value P-value P-value
Number of patients 696 718 3371 3367
Male (n, %) 269 38.6 299 41.6 2032 60.3 2038 60.5 o0.0001 0.56 0.34
Female (n, %) 427 61.4 419 58.4 1339 39.7 1329 39.5 — — —
Age (years) (mean, s.d.) 67.05 6.85 66.62 6.91 68.68 7.00 68.62 7.02 o0.0001 0.41 0.36
Mean systolic BP (mean, s.d.) 145.11 18.65 144.77 18.05 141.62 17.22 142.00 17.16 o0.0001 0.49 0.48
Mean diastolic BP (mean, s.d.) 81.31 10.22 81.29 10.63 77.57 10.41 77.71 10.27 o0.0001 0.56 0.79
Heart rate (beats/min; mean, s.d.) 72.96 10.79 73.08 10.83 70.58 10.42 70.49 10.81 o0.0001 0.86 0.73
Body mass index (kg/m2)a (mean, s.d.) 33.19 7.23 33.09 6.85 31.54 6.39 31.57 6.54 o0.0001 0.92 0.73
Fasting blood glucose (mg/dl; mean, s.d.) 132.23 60.17 131.42 56.33 126.30 45.74 125.20 45.18 o0.0001 0.34 0.92
Estimated glomerular filtration rate
(eGFR) – ml/min per 1.73 m2 of body
surface area (SA)
(ml/min per SA)b (mean, s.d.)
85.42 25.15 85.77 25.07 79.00 21.66 79.08 22.10 o0.0001 0.75 0.83
Prior coronary artery disease (n, %) 211 30.3 231 32.2 1744 51.7 1725 51.2 o0.0001 0.87 0.39
Prior stroke (n, %) 97 14.0 118 16.4 381 11.3 360 10.7 o0.0001 0.94 0.13
Renal diseasec (n, %) 79 11.4 86 12.0 213 6.3 197 5.9 o0.0001 0.66 0.46
Left ventricular hypertrophyd (n, %) 123 17.7 137 19.1 352 10.4 332 9.9 o0.0001 0.78 0.32
Number of BP medication classes before study
0 (n, %) 24 3.4 26 3.6 63 1.9 79 2.3 0.0013 0.20 0.59
1 (n, %) 140 20.1 121 16.9 763 22.6 743 22.1 — — —
2 or more (n, %) 532 76.4 571 79.5 2545 75.5 2545 75.6 0.0487 0.51 0.21
Lipid-lowering agents (n, %) 383 55.0 417 58.1 2412 71.6 2468 73.3 o0.0001 0.06 0.76
b-Blockers (n, %) 211 30.3 261 36.4 1555 46.1 1559 46.3 o0.0001 0.30 0.03
Calcium channel blockers (n, %) 339 48.7 319 44.4 1172 34.8 1169 34.7 o0.0001 0.50 0.15
Antiplatelet agents (n, %) 332 48.5 383 53.9 2293 68.2 2280 67.8 o0.0001 0.61 o0.05
Diabetes mellitus (n, %) 514 73.9 526 73.3 2094 62.1 2074 61.6 o0.0001 0.65 0.95
eGFR (ml/min per SA) o30 (n, %) 5 0.7 2 0.3 20 0.6 18 0.5 0.7513 0.44 0.34
eGFR (ml/min per SA) 30 to o60 (n, %) 102 14.7 111 15.5 646 19.2 633 18.8 — — —
eGFR (ml/min per SA) 60 to o90 (n, %) 300 43.4 293 40.8 1788 53.2 1808 53.8 — — —
eGFR (ml/min per SA) X90 (n, %) 285 41.2 312 43.5 909 27.0 900 26.8 o0.0001 0.78 0.39
UACR (mg/g)e (mean, s.d.) 177.5 601.0 147.9 430.4 100.5 311.6 94.6 319.2 o0.0001 0.29 0.33
UACR (mg/g)e (median) 15.26 17.58 12.50 13.24 — — —
UACR (mg/g)e (Q1, Q3) 5.16 76.98 5.49 71.79 5.05 46.78 5.17 43.53 — — —
Log(UACR) (mg/g)e (mean, s.d.) 3.15 1.86 3.16 1.80 2.90 1.64 2.87 1.60 o0.0001 0.75 0.75
UACR (mg/g)e o30 (n, %) 333 60.5 337 59.9 1634 67.2 1619 67.7 o0.0001 0.84 0.70
UACR (mg/g)e 30–300 (n, %) 156 28.4 166 29.5 611 25.1 612 25.6 — — —
UACR (mg/g)e 4300 (n, %) 61 11.1 60 10.7 186 7.7 159 6.7 o0.0001 0.21 0.64
Abbreviations: BP, blood pressure; B+A, benazepril and amlodipine; B+H, benazepril and hydrochlorothiazide.
aThe body mass index is the weight in kilograms divided by the square of the height in meters.
bThe eGFR was calculated with the use of the Modification of Diet in Renal Disease Study equation.
cRenal disease was determined by the investigator on the basis of either a serum creatinine level of more than 1.5 mg/dl (133 ı`mol/l) in women or greater than 1.7 mg/dl
(150mmol/l) in men or the presence of macroalbuminuria, confirmed on two separate occasions at least 48 h apart.
dLeft ventricular hypertrophy was determined on the basis of electrocardiographic findings (central reading).
eN for baseline UACR (urine albumin/creatinine ratio (mg/g)): 1113 for Blacks (550 B+A, 563 B+H), 4821 for non-Blacks (2431 B+A, 2390 B+H).
Note: Of the 6738 non-Black patients, 6283 (93.2%) were Caucasian and 455 (6.8) were of another race.
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interaction, only less use of b-blockers or antiplatelet agents
was significant in the Black BþA group.
Among the self-described US Blacks, mean BP following
titration was 133.6/75.1 mm Hg in the BþA group and
133.9/75.5 mm Hg in the BþH group (mean difference
0.3/0.4 mm Hg; P¼ 0.72/0.33). In the US non-Black group,
the mean BP following titration was 129.1/71.2 mm Hg in the
BþA group and 129.7/72.3 mm Hg in the BþH group
(mean difference 0.6/1.1 mm Hg; P¼ 0.047/o0.001). For all
patients, mean blood pressure control o140/90 (o130/80)
mm Hg following titration was 75.4% (43.4%) and 72.3%
(41.8%) in the BþA and BþH groups, respectively
(Po0.001 (P¼ 0.014)). Similarly, in the US Blacks, mean
blood pressure control o140/90 (o130/80) mm Hg follow-
ing titration was 70.2% (38.5%) and 68.9% (38.6%) in the
BþA and BþH groups, respectively (P¼ 0.470 (P¼ 0.918))
and that in US non-Blacks was 80.8% (51.7%) and 78.8%
(49.9%) in the BþA and BþH groups, respectively
(P¼ 0.003 (P¼ 0.033)).
More details about baseline characteristics, primary end
points, blood pressure levels, and safety data for the entire
cohort were reported previously.18
Incidence of kidney disease progression based on
race/ethnicity
As seen in Table 2, there was no overall difference in
adjudicated renal outcomes of doubling of serum creatinine,
end-stage renal disease, or death or cardiovascular death
between Blacks and non-Blacks. The overall composite of
cardiovascular mortality and morbidity was less frequent in
Blacks (7.8 vs. 12.1%; Po0.001).
As seen in Table 2 and Figure 1, there was no ethnic
difference in renal end points other than a 450% increase in
creatinine with a serum creatinine above 2.6 mg/dl (2.1 vs.
1.2%; P¼ 0.001). There was no evidence of a baseline kidney
disease interaction by ethnicity. These observations were
consistent, despite adjustment for all potential demographic
and baseline clinical variables.
In an effort to separate the effect of prior antihypertensive
therapy before the study and acute hemodynamic effects of
randomized therapy (BþA vs. BþH), we calculated the
mean change in estimated glomerular filtration rate (eGFR)
from both baseline and also from month 3 of the study
(Figures 2 and 3). We detected no difference between Blacks
and non-Blacks for a mean change of eGFR when calculated
from baseline (5.3 vs. 5.8 ml/min per 1.73 m2 at final visit;
P¼ nonsignificant) or from month 3 (3.0 vs. 2.9 ml/min
per 1.73 m2 at final visit; P¼nonsignificant).
The effects of combination therapy on renal outcomes in
Blacks
For the composite adjudicated renal outcomes of doubling of
serum creatinine, end-stage renal disease, or death, there was
no difference between treatment outcomes among Black
patients (Table 3). In addition, the risk of a 450% increase in
creatinine or adjudicated renal end point did not differ
between treatments among Blacks (Figure 4). When we
calculated the mean change in eGFR from baseline in Blacks
treated with BþA and BþH, there was a significant
difference (0.5 vs. 9.8 ml/min per 1.73 m2 at final visit;
Po0.001). Using the random coefficient model with an
unstructured covariance matrix the difference in slope was
significant (Po0.02). However, when calculated from 3
months, the difference was not statistically different (2.3 vs.
3.6 ml/min per 1.73 m2 at final visit; P¼nonsignificant),
nor was the slope different using the random coefficient
model. Moreover, as depicted in Figure 3, there was no
difference in slope of change after 3 months between BþA
and BþH treatments among Blacks, but a difference was
Table 2 | Analysis of renal end points based on self-described ethnicity (US patients)
Black (n=1414) Non-Black (n=6738) Log-rank (P value)
CV death, doubled creatinine, or ESRD 30 (2.1%) 194 (2.9%) 0.281
Death, doubled creatinine, or ESRD 57 (4.0%) 354 (5.3%) 0.249
Greater than 50% increase in creatinine 12.5% 12.9% 0.403
Greater than 50% increase in creatinine and adjudicated renal end point 12.7% 13.1% 0.437
Greater than 50% increase in creatinine and CV death 13.8% 14.8% 0.731
Greater than 50% increase in creatinine and above normal range 9.7% 9.3% 0.123
Greater than 50% increase in creatinine and 42.6 mg/dl 2.1% 1.2% 0.001
Abbreviations: CV, cardiovascular; ESRD, estimated glomerular filtration rate.
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Figure 1 |Kaplan–Meier curves for the composite end point of
more than 50% increase in serum creatinine or adjudicated
renal end point—by self-described ethnicity (US patients).
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observed among non-Blacks. As depicted in Table 4, Blacks
were more likely to shift from micro- to macro-albuminuria
on BþA compared with BþH, whereas patients on BþH
were more likely to revert from micro- to normo-albumi-
nuria (although these results are based on only 221 of 696
Black BþA patients and 223 of 718 Black BþH patients).
We evaluated race/ethnicity by drug interaction for the
subgroups with urine albumin-to-creatinine ratio (UACR)
o30 and 4300. Neither was statistically significant.
The effects of combination therapy on renal outcomes in
non-Black patients
Non-Blacks when treated with BþA had a statistically signifi-
cantly lower risk for developing a 450% increase in serum
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Figure 2 |Mean change from baseline in estimated glomerular filtration rate (eGFR) by race/ethnicity and treatment groups
(US patients); slope difference calculated from baseline between BþA and BþH in Blacks (Po0.02) and non-Blacks (Po0.0001).
BþA, benazepril and amlodipine; BþH, benazepril and hydrochlorothiazide; Blk, Black; CI, 95% confidence interval.
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Figure 3 |Mean change from month 3 in estimated glomerular filtration rate (eGFR)—by race/ethnicity and treatment group
(US patients); slope difference between BþA and BþH calculated from month 3: Blacks (P¼ 0.785) and non-Blacks (P¼ 0.022).
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creatinine alone, or in combination with a variety of other end
points, compared with treatment with BþH (Figure 4).
When non-Blacks had their mean eGFR change calculated
from baseline, the difference between BþA and BþH
treatments was significantly different (2.6 vs. 9.1 ml/min
per 1.73 m2 at final visit; Po0.0001). Using the random coeffi-
cient model the slope was significantly different (Po0.0001).
Similarly, when calculated from month 3, the mean loss of
eGFR was less in the BþA group (1.9 vs. 3.9 ml/min per
1.73 m2; Po0.0001). When using the random coefficient
model the slope difference was still statistically significant
(Po0.02). There was also a less negative slope with BþA
compared with BþH (Figure 3; P¼ 0.016). In addition, as
shown in Figure 5, because of the large number of non-Blacks
in the study, there was a difference in all US patients regardless
of ethnicity in favor of BþA over BþH on change in slope
(P¼ 0.035). As in Black participants, non-Blacks demon-
strated less shift from micro- to macro-albuminuria with
treatment with BþH and a greater likelihood of normal-
ization of albuminuria with BþH compared with BþA
(based on 823 of 3317 BþA non-Black patients and 798
of 3367 BþH non-Black patients, Table 4). The clinical
relevance of these observations is not known, relative to the
improved stabilization of eGFR in the BþA group. It may be
related to different glomerular hemodynamic effects of the
combination therapies.
Acute influence of randomized therapy on eGFR
Figure 2 illustrates the mean change in eGFR over time by
race/ethnicity and treatment group. Note the substantial
difference of BþA compared with BþH on eGFR during
the first 3 months. For this reason, we recalculated the mean
loss of eGFR from baseline and from month 3. In Figure 3,
note that the slope of change in eGFR from month 3 to
month 36 is no different among Blacks whether on BþA
(0.21 (0.16, 0.26)) or BþH (0.20 (0.16, 0.25)),
Table 3 | Analysis of primary adjudicated end points based
for US Blacks, based on treatment
B+A
(n=696)
B+H
(n=718)
Log rank
(P-value)
Primary endpoint:
CV mortality-morbidity
46 (6.6%) 64 (8.9%) 0.102
CV mortality 8 (1.1%) 10 (1.4%) 0.628
MI: Fatal–non-fatal 9 (1.3%) 13 (1.8%) 0.434
Stroke: Fatal–non-fatal 15 (2.2%) 15 (2.1%) 0.970
Hospitalization for unstable angina 6 (0.9%) 9 (1.3%) 0.459
Hospitalization for CHF 12 (1.7%) 16 (2.2%) 0.497
Coronary revascularization 23 (3.3%) 35 (4.9%) 0.141
CV death, doubled creatinine, or ESRD 15 (2.2%) 15 (2.1%) 0.974
Death, doubled creatinine, or ESRD 27 (3.9%) 30 (4.2%) 0.749
Abbreviations: B+A, benazepril and amlodipine; B+H, benazepril and hydrochloro-
thiazide; CHF, congestive heart failure; CV, cardiovascular; ESRD, estimated
glomerular filtration rate; MI, myocardial infarction.
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Figure 4 |Kaplan–Meier curves for the composite end point
of 450% increase from month 3 in serum creatinine or
adjudicated renal end point after month 3—by race/ethnicity
and treatment group (US patients). BþA, benazepril and
amlodipine; BþH, benazepril and hydrochlorothiazide; Blk, Black.
Table 4 | Shift from normo/microalbuminuria/clinical
albuminuria based on ethnicity and treatment
Race: Blacksa
B+Ab (n=696) Baseline, n (%) End of studyc,d
a. UACRo30e 60 (27.1) 59 (26.7)
b. UACR 30–300 116 (52.5) 94 (42.5)
c. UACR4300 45 (20.4) 68 (30.8)
Total 221 (100) 221 (100)
B+Hf (n=718) Baseline, n (%) End of studyd,g
a. UACRo30 57 (25.6) 81 (36.3)
b. UACR 30–300 124 (55.6) 93 (41.7)
c. UACR4300 42 (18.8) 49 (22.0)
Total 223 (100) 223 (100)
Race: non-Blackh
B+A (n=3371) Baseline, n (%) End of studyi,j
a. UACRo30 187 (22.7) 233 (28.3)
b. UACR 30–300 494 (60.0) 376 (45.7)
c. UACR4300 142 (17.3) 214 (26.0)
Total 823 (100) 823 (100)
B+H (n=3367) Baseline, n (%) End of studyj,k
a. UACRo30 193 (24.2) 293 (36.7)
b. UACR 30–300 475 (59.5) 376 (47.1)
c. UACR4300 130 (16.3) 129 (16.2)
Total 798 (100) 798 (100)
aP-values for homogeneity of odds ratios for 2 2 groupings: 0.656 for a vs. b and c;
0.049 for a and b vs. c.
bB+A, benazepril and amlodipine.
cP=0.002 (within treatment comparison of baseline vs. maximum post baseline).
dP=0.001 (Cochran–Mantel–Haenszel test for between-treatment comparison,
stratified for baseline values).
eAll UACR (urine albumin/creatinine ratios) expressed as mg albumin/g creatinine.
fB+H, benazepril and hydrochlorothiazide.
gP=0.003 (within treatment comparison of baseline vs. maximum post baseline).
hP-values for homogeneity of odds ratios for 2 2 groupings: 0.051 for a vs. b and c;
0.860 for a and b vs. c.
iPo0.0001 (within treatment comparison of baseline vs. maximum post baseline).
jPo0.0001 (within treatment comparison of baseline vs. maximum post baseline).
kPo0.0001 (Cochran–Mantel–Haenszel test for between-treatment comparison,
stratified for baseline values).
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P¼nonsignificant. However, non-Blacks had a less negative
slope with BþA (0.18 (0.15, 0.20)) compared with
BþH (0.21 (0.19, 0.23)), P¼ 0.016.
Multivariable assessment of renal outcomes
To evaluate the contribution of various demographic and
clinical variables for time to first event of 450% increase in
serum creatinine or adjudicated renal end point, we used
clinical data from only 3 months onward in order to avoid
the acute hemodynamic effects of randomized therapy. We
used a multivariable Cox regression model incorporating all
of the variables in Table 1. We utilized a stepwise regression
model with Black race/ethnicity and BþA treatment as
required variables and included all the remaining variables
(generated from Table 1) if they met the following criteria:
(a) for all variables not in the model, the one with the
smallest P-value was entered if the P-value was p0.005; and
(b) for all variables included in the model, the one with the
largest P-value was removed if the P-value exceeded 0.001.
This procedure was performed to include the natural
logarithm of UACR as a potential covariate, which decreased
the number of patients available for the study by about 28%
(from 7156 patients without baseline UACR to 5179 with
baseline UACR). As can be seen in Table 5, BþA therapy and
male gender are associated with less risk of CKD progression,
whereas baseline eGFR o60 ml/min per 1.73 m2 and an
increase in the natural log of UACR were associated with
increased risk.
DISCUSSION
The ACCOMPLISH study provides an important opportu-
nity to examine the acute and chronic influence of randomi-
zed combination therapy on renal outcomes in Blacks and
non-Blacks.
The main observation is that Blacks at high cardiovascular
risk demonstrated a greater propensity for 50% increase in
serum creatinine above 2.6 mg/dl compared with their non-
Black counterparts. BþA therapy was no different from
BþH therapy in retarding the rate of progression of kidney
disease in Blacks. On the other hand, BþA therapy was more
effective than BþH therapy in non-Blacks in slowing down
the mean loss of eGFR. Of importance, these findings were
significant even after statistical adjustment for confounding
baseline clinical and demographic factors.
A variety of explanations have been offered as to why
Blacks may be at greater risk for progressive renal injury
compared with their non-Black counterparts. Some have
suggested that there may be genetic factors;19 others suggest
that there may be sociocultural and ethnic differences that
increase risk for kidney disease progression in a susceptible
population such as Blacks.1–11 Unlike prior observations,
our results provide evidence that hypertensive Blacks with
cardiovascular disease or with cardiovascular disease risk
factors derive substantial benefit with regard to prevention of
progressive renal insufficiency from effective multidrug
antihypertensive regimens. A prior study has documented
that hypertensive Blacks with chronic kidney disease, if
treated with a RAS-blocking drug (ACE inhibitor) in
addition to other medicines that lower blood pressure, will
have fewer kidney and cardiovascular disease end points.16
However, what was not known before this study is whether
there may be differences in long-term outcomes when pairing
an ACE inhibitor with other commonly used antihyperten-
sive drugs, such as a thiazide diuretic or a calcium channel
blocker.
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Figure 5 |Mean change from month 3 in estimated glomerular
filtration rate (eGFR)—by treatment group (US patients);
slope difference calculated from month 3 between BþA and
BþH is P¼ 0.035. BþA, benazepril and amlodipine; BþH,
benazepril and hydrochlorothiazide; Blk, Black; CI, 95% confidence
interval.
Table 5 | Significant variables from the stepwise Cox
regression of the renal end point: time to first event for
450% increase in creatinine from month 3 or adjudicated
renal end point (end-stage renal disease or doubling of
creatinine) after month 3
Variable N HR LCL UCL w2 P-value
Black racea 5179 0.873 0.686 1.110 1.23 0.2677
Benazepril/amlodipine
treatmenta
5179 0.768 0.642 0.919 8.33 0.0039
Natural log of baseline
UACR
5179 1.209 1.149 1.272 53.32 o0.0001
Male sex 5179 0.675 0.564 0.809 18.09 o0.0001
Baseline GFRo60 ml/min
per 1.73 m2
5179 1.463 1.194 1.792 13.47 0.0002
Abbreviations: GFR, glomerular filtration rate; HR, hazard ratio; LCL/UCL, lower and
upper boundaries of 95% confidence interval for HR.
aBlack race and treatment with benazepril and amlodipine were required variables in
the final stepwise regression models.
Note: The natural log of UACR (urine albumin/creatinine ratio) was in the analysis.
Variables were included in the stepwise regression if they met the following criteria:
(1) For all variables not in the model, the one with the smallest P-value is entered if
the P-value is less than or equal to a specified significance level of 0.005.
(2) For all variables in the model, the one with the largest P-value is removed if the
P-value exceeds a specified significance level of 0.001.
Some form of all variables in Table 1 was included as candidate variables in the
initial stepwise regression model.
Kidney International (2012) 81, 568–576 573
MR Weir et al.: Hypertension treatment and kidney disease in Blacks o r ig ina l a r t i c l e
The acute hemodynamic effects of BþA and BþH
require some comment. Thiazide diuretics, alone, result in
only modest changes in blood volume when dosed chroni-
cally.20 Yet, when combined with a RAS-blocking drug, even a
dose of 25 mg results in a substantial change in eGFR during
the first 3 months (Figure 2). These observations are of
clinical relevance even in patients with eGFR of around
80 ml/min per 1.73 m2 as in our study and may be even more
substantial in patients with lower levels of eGFR. Conse-
quently, a 3-month time point may be the more appropriate
time to start slope calculations contrasting different thera-
pies, especially if they contain diuretics (loop or thiazide) and
RAS inhibitors.
The differences in the upward shift of proteinuria in both
Blacks and non-Blacks with BþA vs. BþH mirrored the
changes seen in the main study.21 How best to interpret these
observations is problematic given the small number of
measures, but it may be related to the acute glomerular
hemodynamic changes of randomized therapy on eGFR.
An important observation of this report is that for non-
Black participants a blood pressure-lowering regimen based
on an ACE inhibitor and calcium channel blocker combina-
tion resulted in a lower risk for a 450% increase in serum
creatinine, alone and combined with other end points.16
What is the mechanism of this benefit of BþA vs. BþH
in non-Blacks? Might there be differences in the achieved
levels of central aortic blood pressure? A recently published
study22 suggests that central aortic blood pressure is lower if
hypertensive patients receive a RAS-blocking drug with a
calcium blocker as opposed to a thiazide diuretic. As the
blood supply to the kidneys emanates from the aorta,
perhaps central aortic blood pressure measurements rather
than brachial artery measurements would be more effective
in predicting a beneficial response to blood pressure
treatment goals and types of antihypertensive medication.
Other possibilities include direct vascular effects, which may
differ between a calcium channel blocker and a thiazide
diuretic. However, this is purely speculative. How can we
reconcile these considerations relative to the lack of difference
of randomized therapy in Blacks? Is this just a problem of
power, with too few Blacks compared with non-Blacks for
evaluating the influence of treatment?
Unfortunately, further subdividing the relatively small
group of Blacks based on the presence or absence of diabetes,
or more advanced impairment of eGFR, was not possible
because of the insufficient size of the subgroups. Approxi-
mately 61% of the entire cohort had diabetes. A further
examination of this group yielded no differences compared
with examined outcomes in the whole cohort. As has been
reported previously, approximately 70% of the patients with
normal kidney function had normal levels of albuminuria,
whereas 53% of the group with eGFRo60 ml/min per
1.73 m2 had either micro- or macro-albuminuria. Although
both therapeutic arms reduced albuminuria, further subdivi-
sion of this group based on ethnicity diluted the number of
patients for analysis.
Our observations are clinically relevant, but they do have
limitations. The ACCOMPLISH study was terminated early
because of the advantage of the BþA group on composite
cardiovascular morbidity and mortality. This limited our
opportunity for considering specific kidney disease end
points based on ethnicity. However, modifying our assess-
ment by including an increase in serum creatinine 450%
over baseline, albeit arbitrary, is of clinical relevance.
Moreover, combining this modified variable with adjudicated
kidney and cardiovascular end points demonstrated the
remarkable neutralization of renal events in the Black
population, relative to the non-Black population, with early
use of combination therapy. This, we believe, is a testament
to the value of both more prompt control of blood pressure
and blockade of RAS.
Thus, we conclude that these unique observations from
the ACCOMPLISH study add to our clinical understanding
about hypertension treatment strategies in Black and non-
Black populations. Moreover, it provides observations on the
best approach for controlling blood pressure and how we can
reduce the risk for kidney disease progression in this higher
risk population, specifically in individuals who are middle-
aged and older, overweight, and frequently with type 2
diabetes and still have reasonably well-preserved GFR.
Future studies will be needed to examine in more detail
why lowering blood pressure in non-Blacks with an ACE
inhibitor-based therapy combined with a calcium channel
blocker rather than a thiazide diuretic was more effective in
reducing the mean loss of eGFR despite similar levels of
brachial artery blood pressure.
MATERIALS AND METHODS
The ACCOMPLISH trial rationale and design has been reported
previously.18 Briefly, this trial was a prospective randomized double-
blind clinical trial conducted in five countries (USA, Sweden,
Norway, Denmark, and Finland). For the purposes of this analysis,
we evaluated only US participants (n¼ 8152), as all but two Black
participants were from the United States. Study participants were
hypertensive with high risk for cardiovascular events including a
history of prior coronary events, myocardial infarction, revascular-
ization, stroke, chronic kidney disease, peripheral arterial disease,
left ventricular hypertrophy, and diabetes. Detailed eligibility criteria
have been reported previously. All patients gave written consent
before study enrollment. Eligible subjects were randomized to either
a combination of benazepril and amlodipine (BþA) 20/5 mg or a
combination of benazepril and hydrochlorothiazide (BþH) 20/
12.5 mg daily. Patients were switched from prior medications or
were started de novo without any preceding placebo period. One
month after randomization, the ACE inhibitor, B, was force titrated
in both groups to 40 mg daily. At 2 months post randomization, the
A or H component could be increased to 10 or 25 mg, respectively,
to facilitate achievement of a target blood pressure of either
o140/90 or o132/80 mm Hg for patients with diabetes or eGFR
below 60 ml/min per 1.73 m2. Additional medications could be
added after 3 months to facilitate achievement of blood pressure
control, including b-blockers, a-blockers, clonidine, and spirono-
lactone. Once daily, loop diuretics could be given if a volume
component was felt to contribute to blood pressure elevation.
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After the 3-month titration period, patients returned for follow-up
at 6-month intervals.
Estimated GFR was derived using the creatinine-based formula
from the Modification of Diet in Renal Disease Study.17 The
presence of baseline kidney disease was defined as a serum creatinine
greater than 1.5 mg/dl in females or 1.7 mg/dl in males and/or
a UACR greater than 300 mg/g, or greater than 200 mg/g if on
a RAS-blocking drug.
Study end points
The primary end point of the trial was time to first event of
composite cardiovascular morbidity and mortality (sudden cardiac
death, myocardial infarction, stroke, coronary revascularization,
congestive heart failure, or other cardiovascular deaths). The trial
was terminated early (mean of 3.0 years) because of a lower
composite cardiovascular morbidity and mortality event rate in
favor of BþA.18 The prespecified kidney disease end point was time
to first event of doubling of serum creatinine or end-stage renal
disease, defined as eGFR below 15 ml/min per 1.73 m2, or need for
dialysis or transplantation. For the study overall, fewer patients on
BþA (n¼ 33, 0.6%) experienced this end point compared with
those on BþH (n¼ 48, 0.8%, P¼ 0.0953). Because the trial was
stopped early, limiting the power to evaluate longitudinal changes in
kidney function in subgroups, we undertook a post hoc modification
of the end point of kidney disease progression to include a 450%
increase in serum creatinine, or end-stage renal disease. To ensure
that we had excluded possible confounding of long-term changes in
renal function by acute hemodynamic effects of randomized
therapy, we compared the mean rate of loss of eGFR from baseline
and also after 3 months of randomized therapy. Other end points
evaluated in this analysis included a 450% increase in serum
creatinine, and creatinine greater than upper limits of normal
(41.2 mg/dl for females and 41.3 mg/dl for males), and also a
450% increase in creatinine with a creatinine level 42.6 mg/dl
(two times the upper limit of normal for men). We have also
evaluated the composite end point of 450% creatinine over
baseline and cardiovascular death.
Statistical analysis
The ACCOMPLISH trial was designed to be an event-driven study
to accrue 1642 patients with primary events, providing 90% power
to detect a 15% risk reduction for the BþA group at a two-sided
significance level of 0.05 assuming an annual event rate of 3.5% for
the BþH group. An independent data-monitoring committee
reviewed all events. An adjudication committee, whose members
were unaware of study group assignments, evaluated all prespecified
end points using standard criteria. The analysis of all efficacy
end points followed the intention-to-treat principle. The current
comparisons were based on self-described ethnicity subgroups.
Baseline comparisons were made with w2-tests for categorical
variables and with F-tests for continuous variables. Kaplan–Meier
methods were used to construct cumulative time-to-event curves for
each group. The primary comparison was based on a log-rank test.
A univariate Cox regression, which included only treatment in the
model, was performed for time to first primary event to obtain the
point estimate and 95% confidence interval for the hazard ratio
between groups. Superior efficacy for the BþA treatment group was
concluded if the log-rank test was significant and Cox regression
showed risk reduction in favor of BþA. Time to first event analyses
using similar log-rank tests and univariate Cox regression were also
performed for each component of the primary end point and for
other time-to-event efficacy end points. Analyses for each end point
were performed without censoring for other types of prior events
so that all patients had complete information included for the
respective end points. More details regarding these statistical
analyses and study design have been published previously.18 We
also used a multivariable Cox regression model with all of the
clinical and demographic variables. We then utilized a stepwise
regression model with Black race/ethnicity and BþA treatment as
required variables and evaluated in a stepwise manner the inclusion
of various clinical and demographic variables.
Slope values (representing change in eGFR per month) were
estimated for each of the four race and treatment group combi-
nations using a random coefficient mixed-effects model with an
unstructured covariance matrix, with change from baseline (or
change from month 3) as the dependent variable and scheduled
month as the independent variable. Separate slope and intercept
values were estimated for each patient, using restricted maximum
likelihood estimation, to obtain overall slope estimates for each race
and treatment group combination.
The shift from normo- to micro- or from micro- to macro-
albuminuria was evaluated using the Cochran–Mantel–Haenzel test
for between-treatment comparisons, stratified by baseline values.
P-values for homogeneity of odds ratios were analyzed for 2 2
groupings. All continuous data have been reported as mean±s.d.
All P-values are two sided.
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